Research Papers:
Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2519 views | HTML 3557 views | ?
Abstract
Melanie J. McCoy1,4, Chris Hemmings2,3, Chidozie C. Anyaegbu1, Stephanie J. Austin1,3, Tracey F. Lee-Pullen1,3, Timothy J. Miller1,3, Max K. Bulsara5, Nikolajs Zeps1,3, Anna K. Nowak4,6, Richard A. Lake4, Cameron F. Platell1,3
1Colorectal Research Unit, St John of God Subiaco Hospital, Subiaco, WA, 6008, Australia
2Department of Anatomic Pathology, St John of God Pathology, Wembley, WA, 6014, Australia
3School of Surgery, University of Western Australia, Crawley, WA, 6009, Australia
4School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, 6009, Australia
5Institute for Health Research, University of Notre Dame, Fremantle, WA, 6959, Australia
6Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia
Correspondence to:
Melanie McCoy, email: [email protected]
Keywords: rectal cancer, regulatory T cells, radiotherapy, chemotherapy, treatment response
Received: September 13, 2016 Accepted: January 07, 2017 Published: February 03, 2017
ABSTRACT
Neoadjuvant (preoperative) chemoradiotherapy (CRT) decreases the risk of rectal cancer recurrence and reduces tumour volume prior to surgery. However, response to CRT varies considerably between individuals and factors associated with response are poorly understood. Foxp3+ regulatory T cells (Tregs) inhibit anti-tumour immunity and may limit any response to chemotherapy and radiotherapy. We have previously reported that a low density of Tregs in the tumour stroma following neoadjuvant CRT for rectal cancer is associated with improved tumour regression. Here we have examined the association between Treg density in pre-treatment diagnostic biopsy specimens and treatment response, in this same patient cohort. We aimed to determine whether pre-treatment tumour-infiltrating Treg density predicts subsequent response to neoadjuvant CRT. Foxp3+, CD8+ and CD3+ cell densities in biopsy samples from 106 patients were assessed by standard immunohistochemistry (IHC) and evaluated for their association with tumour regression grade and survival. We found no association between the density of any T cell subset pre-treatment and clinical outcome, indicating that tumour-infiltrating Treg density does not predict response to neoadjuvant CRT in rectal cancer. Taken together with the findings of the previous study, these data suggest that in the context of neoadjuvant CRT for rectal cancer, the impact of chemotherapy and/or radiotherapy on anti-tumour immunity may be more important than the state of the pre-existing local immune response.
![Creative Commons License](/images/80x15.png)
PII: 15048